Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01333098 · ClinicalTrials.gov registry record · Phase 1
Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders
A Phase 1 study of Anxiety Disorders, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT01333098 is a Phase 1 study of Anxiety Disorders that has completed, run by Washington University School of Medicine. The registered enrollment target is 15 participants, below the 1,140-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01333098, a Phase 1 study of Anxiety Disorders, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to develop and test a novel, mechanistic treatment for mitigating cognitive impairment in older adults with anxiety disorders. Anxiety disorders are common, severe, and disabling in older adults. One particularly impairing aspect of late-life anxiety disorders is cognitive impairment: impairments in memory and executive function cause disability, impede treatment response to psychotherapy, may lead to dementia, and are not corrected by standard anti-anxiety treatments. This pilot study will test the glucocorticoid antagonist, mifepristone, for cognitive impairment in late-life anxiety disorders. Mifepristone blocks the effects of elevated cortisol levels on glucocorticoid receptors in the brain; it has been studied preliminarily in various neuropsychiatric disorders, such as psychotic depression and bipolar disorder, with well-documented safety and tolerability.
Conditions Studied
Interventions
- DRUG Mifepristone
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01333098
The ClinicalTrials.gov registry entry for NCT01333098 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,140-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (99% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anxiety Disorders appearing as the primary indexed condition, and to 1 intervention - of which Mifepristone is the first listed.
NCT01333098 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT01333098 about?
NCT01333098 is a clinical study titled "Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders". This study seeks to develop and test a novel, mechanistic treatment for mitigating cognitive impairment in older adults with anxiety disorders. Anxiety disorders are common, severe, and disabling in older adults. One particularly impairing aspect of late-life anxiety disorders is cognitive impairmen...
What is the current status of trial NCT01333098?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2012-09. Estimated completion is 2013-04.
What conditions does trial NCT01333098 study?
This clinical trial studies the following conditions: Anxiety Disorders.
What interventions are being tested in trial NCT01333098?
The interventions under investigation include: Mifepristone (DRUG).
Who is sponsoring clinical trial NCT01333098?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01333098 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mindfulness-based Stress Reduction and Cognitive Function in Stress and Aging
COMPLETED · Phase 1
-
Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders
COMPLETED · Phase 1
-
Treatment for Specific Phobias in Children
COMPLETED · Phase 1
-
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
RECRUITING · NA
-
CRISOL Mente: A Multilevel Community Intervention to Reduce Mental Health Disparities Among Latinos
RECRUITING · NA
-
Trial With the Treatment of Sertraline in Youth With Generalized, Separation and/or Social Anxiety Disorders.
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.